11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence

J.M.S Bartlett,Y Zhang,I Ahmed,K Treuner,T Piper,S.J Pirrie,A.M Brufsky,D.C Sgroi,C.A Schnabel,D.W Rea

doi:10.1016/j.annonc.2021.03.025

11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence

J.M.S Bartlett, Y Zhang + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2021.03.025

Copy DOI

Journal: Annals of Oncology	Publication Date: May 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Cancer Research UK Clinical Trials Unit, University of Birmingham, Biothera (United States), University of Edinburgh

#Breast Cancer Index #Late Distant Recurrence + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BCI is a gene expression-based assay that reports a prognostic score for risk of overall (10y) and late (≥5y) distant recurrence (DR) in HR+ early-stage breast cancer. The current study optimized the BCI prognostic model for late DR utilizing N0 patients from the translational aTTom (Trans-aTTom) study.

Full Text